This study was sponsored by Daiichi Sankyo Europe. V Guarneri has received personal fees for advisory board membership for AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Pfizer and Olema Oncology. She has received personal fees as an invited speaker for AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK and Novartis. She has received personal fees for expert testimony for Eli Lilly. She has received institutional funding as a local PI for AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, GSK, Merck, MSD, Nerviano, Novartis, Pfizer, Roche and Synton Biopharmaceutical. J-Y Pierga received travel funds from AstraZeneca, Eli Lilly, Gilead, MSD, Pfizer and Seagen. He has received consultancy/speaker fees from Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Menarini Stemline, MSD, Novartis, Pfizer, Roche, Seagen and Veracyte. FP Duhoux has received funding for a postdoctoral clinical mandate from the not-for-profit organization ‘Foundation Against Cancer’ (grant number: 2022-053). He has received consulting fees from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Seagen. He has received travel support from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Novartis, Pfizer, Pierre Fabre, Roche and Seagen. JA García-Sáenz has received consultive and advisory services from Seagen, AstraZeneca, Daiichi Sankyo, Novartis, Gilead and Menarini. He has received consultancy/speaker fees from Celgene, Eli Lilly, Eisai, MSD, Exact Sciences, Tecnofarma, Nolver (Adium), Asofarma and Roche. He has received institution and research funding from AstraZeneca, and travel support from Gilead, AstraZeneca, and Daiichi Sankyo. H Wildiers has received financial compensation for his institution on his behalf for advisory boards, lecture fees and/or consultancy fees from Daiichi Sankyo, Eli Lilly, Gilead, Pfizer, Novartis, MSD, Relay Therapeutics, PSI, Augustine Therapeutics, AstraZeneca, Roche. He received travel support from Gilead, Daiichi Sankyo and Pfizer. D Egle has received financial compensation for his institution on his behalf for advisory boards, lecture fees and/or consultancy fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche and Sirius Medical. He received travel support from AstraZeneca, Daiichi Sankyo, Gilead and Pfizer. JL Passos Coelho has participated in Advisory Boards for AstraZeneca, Daiichi Sankyo, Eli Lilly, Janssen, Novartis, Pfizer and Roche. K Selander has received congress invitations from AstraZeneca, Daiichi Sankyo, Gilead and Novartis. F Penault-Llorca has received direct support from AstraZeneca, BMS, Daiichi Sankyo, Eisai, Eli Lilly, Exact Sciences, GSK, Illumina, Invitae, MSD, Myriad, Nanostring, Novartis, Pfizer, Pierre-Fabre, Roche, Veracyte. She has received support through her institution from AstraZeneca and Illumina. She has received congress invitations from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Novartis and Pfizer. K Zaman received financial compensation for his institution on his behalf for Advisory Boards from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pierre Fabre, Seagen and Viatris. He has Steering Committee Membership from Daiichi Sankyo and Pierre Fabre, and membership in a study iDMC (Roche). He received research funding from Roche, and support for participation in international congresses from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Pierre Fabre and Roche. M Lucerna and P Laeis are employees of Daiichi Sankyo Europe GmbH. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed above. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.